The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes.

Autor: Wilson JM; Eli Lilly and Company, Indianapolis, Indiana, USA., Nikooienejad A; Eli Lilly and Company, Indianapolis, Indiana, USA., Robins DA; Eli Lilly and Company, Indianapolis, Indiana, USA., Roell WC; Eli Lilly and Company, Indianapolis, Indiana, USA., Riesmeyer JS; Eli Lilly and Company, Indianapolis, Indiana, USA., Haupt A; Eli Lilly and Company, Indianapolis, Indiana, USA., Duffin KL; Eli Lilly and Company, Indianapolis, Indiana, USA., Taskinen MR; Research Program for Clinical and Molecular Medicine Unit, Diabetes and Obesity, University of Helsinki, Helsinki, Finland., Ruotolo G; Eli Lilly and Company, Indianapolis, Indiana, USA.
Jazyk: angličtina
Zdroj: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2020 Dec; Vol. 22 (12), pp. 2451-2459. Date of Electronic Publication: 2020 Sep 15.
DOI: 10.1111/dom.14174
Abstrakt: Aim: To better understand the marked decrease in serum triglycerides observed with tirzepatide in patients with type 2 diabetes, additional lipoprotein-related biomarkers were measured post hoc in available samples from the same study.
Materials and Methods: Patients were randomized to receive once-weekly subcutaneous tirzepatide (1, 5, 10 or 15 mg), dulaglutide (1.5 mg) or placebo. Serum lipoprotein profile, apolipoprotein (apo) A-I, B and C-III and preheparin lipoprotein lipase (LPL) were measured at baseline and at 4, 12 and 26 weeks. Lipoprotein particle profile by nuclear magnetic resonance was assessed at baseline and 26 weeks. The lipoprotein insulin resistance (LPIR) score was calculated.
Results: At 26 weeks, tirzepatide dose-dependently decreased apoB and apoC-III levels, and increased serum preheparin LPL compared with placebo. Tirzepatide 10 and 15 mg decreased large triglyceride-rich lipoprotein particles (TRLP), small low-density lipoprotein particles (LDLP) and LPIR score compared with both placebo and dulaglutide. Treatment with dulaglutide also reduced apoB and apoC-III levels but had no effect on either serum LPL or large TRLP, small LDLP and LPIR score. The number of total LDLP was also decreased with tirzepatide 10 and 15 mg compared with placebo. A greater reduction in apoC-III with tirzepatide was observed in patients with high compared with normal baseline triglycerides. At 26 weeks, change in apoC-III, but not body weight, was the best predictor of changes in triglycerides with tirzepatide, explaining up to 22.9% of their variability.
Conclusions: Tirzepatide treatment dose-dependently decreased levels of apoC-III and apoB and the number of large TRLP and small LDLP, suggesting a net improvement in atherogenic lipoprotein profile.
(© 2020 Eli Lilly and Company. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: